Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.37 |
| ▸ | CDK1 | P06493 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20860570 | 0.85 | HTR2A (0.43) | HTR2AHTR2CCA12CA1CA2 | |
| SCHEMBL10158105 | 0.78 | HTR2A (0.38) | HTR2AHTR2CCA12CA1CA2 | |
| SCHEMBL15381045 | 0.77 | HTR2A (0.43) | HTR2AHTR2CCA12CA1CA2 | |
| SCHEMBL10157718 | 0.75 | HTR2C (0.47) | HTR2AHTR2CCA12CA1CA2 | |
| SCHEMBL20860581 | 0.74 | HTR2A (0.41) | HTR2AHTR2CCA12CA1CA2 | |
| SCHEMBL17692675 | 0.74 | HTR2A (0.35) | HTR2AHTR2CCA12CA1CA2 | |
| SCHEMBL18531707 | 0.73 | HTR2C (0.34) | HTR2AHTR2CCA12CA1CA2 | |
| SCHEMBL15829114 | 0.72 | LMNA (0.42) | HTR2AHTR2CCA12CA1CA2 | |
| SCHEMBL10157878 | 0.72 | LMNA (0.42) | HTR2AHTR2CCA12CA1CA2 | |
| SCHEMBL10157714 | 0.72 | LMNA (0.42) | HTR2AHTR2CCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3056487-B1 | SYNTHESIS OF ENONE INTERMEDIATE | HARVARD COLLEGE (US) | 2018-02-21 | — | — | EP | disclosed |
| US-8907104-B2 | Synthesis of enone intermediate | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140179929-A1 | SYNTHESIS OF ENONE INTERMEDIATE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-06-26 | — | — | US | disclosed |
| US-8580969-B2 | Synthesis of enone intermediate | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130217886-A1 | SYNTHESIS OF ENONE INTERMEDIATE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-08-22 | — | — | US | disclosed |
| US-8293920-B2 | Synthesis of enone intermediate | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-10-23 | — | — | US | disclosed |
| US-20120029199-A1 | SYNTHESIS OF ENONE INTERMEDIATE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-02-02 | — | — | US | disclosed |
| US-7960559-B2 | Synthesis of enone intermediate | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-06-14 | — | — | US | disclosed |
| US-20110009639-A1 | SYNTHESIS OF ENONE INTERMEDIATE | MYERS ANDREW G | 2011-01-13 | — | — | US | disclosed |
| US-7763735-B2 | modular synthesis of tetracycline analogs through a chiral enone intermediate; efficiency | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-07-27 | — | — | US | disclosed |
| US-20090093640-A1 | modular synthesis of tetracycline analogs through a chiral enone intermediate; efficiency | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217886-A1 | SYNTHESIS OF ENONE INTERMEDIATE | TECR, ECI1, ERAL1 | HTR2A 4737/4885HTR2C 4653/4885CA12 4773/4885 |
| US-20110009639-A1 | SYNTHESIS OF ENONE INTERMEDIATE | TECR, ECI1, ERAL1 | HTR2A 4737/4885HTR2C 4653/4885CA12 4773/4885 |
| US-20090093640-A1 | modular synthesis of tetracycline analogs through a chiral enone intermediate; efficiency | TECR, TSN, TARS2 | HTR2A 4687/4885HTR2C 4665/4885CA12 4763/4885 |
| US-20140179929-A1 | SYNTHESIS OF ENONE INTERMEDIATE | TECR, ECI1, ERAL1 | HTR2A 4737/4885HTR2C 4653/4885CA12 4773/4885 |
| US-20120029199-A1 | SYNTHESIS OF ENONE INTERMEDIATE | TECR, ECI1, ERAL1 | HTR2A 4737/4885HTR2C 4653/4885CA12 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.